Litigation Details for Neurocrine Biosciences, Inc. v. Zydus Pharmaceuticals (USA) Inc. (D. Del. 2022)

Neurocrine Biosciences, Inc. v. Zydus Pharmaceuticals (USA) Inc. (D. Del. 2022)

Docket	1:22-cv-00439	Date Filed	2022-04-01
Court	District Court, D. Delaware	Date Terminated	2023-11-13
Cause	35:271 Patent Infringement	Assigned To	Maryellen Noreika
Jury Demand	None	Referred To
Parties	ZYDUS WORLDWIDE DMCC
Patents	10,065,952; 10,844,058; 10,851,103; 10,851,104; 10,857,137; 10,857,148; 10,874,648; 10,906,902; 10,906,903; 10,912,771; 10,919,892; 10,940,141; 10,952,997; 10,993,941; 11,026,931; 11,026,939; 11,040,029
Attorneys	Steven J. Balick
Firms	Phillips, Goldman, McLaughlin & Hall, P.A.
Link to Docket	External link to docket

Details for Neurocrine Biosciences, Inc. v. Zydus Pharmaceuticals (USA) Inc. (D. Del. 2022)

Date Filed	Document No.	Description	Snippet	Link To Document
2022-04-01				External link to document
2022-04-01	4	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,065,952; 10,844,058; 10,851,103… 1 April 2022 1:22-cv-00439 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Neurocrine Biosciences v. Zydus Pharmaceuticals: Litigation Summary, Ingrezza Patent Analysis, and Generic Entry Risk

Last updated: August 12, 2026

Neurocrine Biosciences, Inc. v. Zydus Pharmaceuticals (USA) Inc., No. 1:22-cv-00439-RGA, is a Hatch-Waxman patent action concerning Zydus' abbreviated new drug application for generic valbenazine, the active ingredient in Neurocrine's Ingrezza product. Neurocrine filed the case in the U.S. District Court for the District of Delaware after receiving Zydus' Paragraph IV certification challenging patents listed for Ingrezza.

The case created a regulatory stay against FDA approval of Zydus' ANDA. The principal commercial issue was whether Zydus could launch generic valbenazine before expiration of Neurocrine's Orange Book-listed patent rights or whether the litigation would preserve Ingrezza's market protection into the 2030s.

What is Neurocrine Biosciences v. Zydus Pharmaceuticals?

Neurocrine sued Zydus under the Hatch-Waxman Act after Zydus notified Neurocrine that it had filed an ANDA seeking approval for generic valbenazine capsules.

Item	Details
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:22-cv-00439-RGA
Plaintiff	Neurocrine Biosciences, Inc.
Defendant	Zydus Pharmaceuticals (USA) Inc.
Product	Ingrezza, valbenazine capsules
Regulatory pathway	ANDA
Legal basis	Hatch-Waxman patent infringement under 35 U.S.C. § 271(e)(2)
Challenge type	Paragraph IV certification
Primary commercial issue	Timing of generic valbenazine approval and launch

The lawsuit was an artificial act of infringement under Section 271(e)(2), which allows a branded company to sue when a generic applicant submits an ANDA that relies on a branded product's FDA approval and challenges listed patents.

What drug and patents were at issue?

Ingrezza contains valbenazine, a vesicular monoamine transporter 2, or VMAT2, inhibitor. FDA approved Ingrezza in 2017 for tardive dyskinesia. The FDA later approved the product for chorea associated with Huntington's disease.

The asserted patent set reflected Neurocrine's protection for the valbenazine molecule, pharmaceutical compositions, and methods of treating movement disorders. Publicly available Ingrezza patent records and litigation materials identify a portfolio that includes patents directed to valbenazine compounds, salts, formulations, and therapeutic use.

What formulations are protected by the Ingrezza patents?

Ingrezza is marketed as oral capsules in multiple strengths, including 40 mg, 60 mg, and 80 mg. Formulation and dosage patents can be important even after an active-ingredient patent expires because an ANDA applicant may need to certify against each Orange Book-listed patent covering the proposed product.

The relevant protection generally falls into four categories:

1. The valbenazine compound and related chemical forms.
2. Pharmaceutical compositions containing valbenazine.
3. Oral dosage forms and capsule formulations.
4. Methods of treating tardive dyskinesia and Huntington's disease-associated chorea.

A generic applicant can attempt to avoid infringement by changing excipients, dosage instructions, manufacturing conditions, or labeling. That strategy does not eliminate risk if the proposed product still falls within a compound or method-of-use claim.

When did Neurocrine file the lawsuit?

Neurocrine filed the action in 2022 in response to Zydus' ANDA challenge. The assigned judge was Richard G. Andrews, U.S. District Judge for the District of Delaware.

The filing triggered the Hatch-Waxman 30-month stay, subject to statutory exceptions. During the stay, FDA generally could not give final approval to the challenged ANDA unless the court entered an earlier judgment or another statutory event terminated the stay.

What was the significance of the Paragraph IV certification?

A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or will not be infringed by the ANDA product. The certification allows the generic company to challenge the patent before launch rather than waiting for expiration.

For Neurocrine, the Paragraph IV notice required immediate enforcement of the Ingrezza patent estate. For Zydus, the filing created the possibility of an earlier market entry and, if the challenge succeeded, 180 days of generic exclusivity as the first qualifying Paragraph IV filer under the ANDA framework.

What was the Orange Book status of Ingrezza?

Ingrezza's Orange Book status is central to the dispute because only patents listed for the reference drug can trigger the principal Hatch-Waxman certification and stay mechanisms.

Neurocrine's listed rights included patents associated with the valbenazine active ingredient and later-issued patents covering formulations, dosing, and therapeutic use. The practical protection period depended on:

• The expiration date of each patent.
• Any patent-term adjustment.
• Any pediatric exclusivity.
• Whether a patent was listed for the specific dosage form.
• Whether Zydus' labeling and formulation fell within the claims.
• Whether the court found the challenged claims valid and infringed.

The Orange Book should be reviewed by patent number and dosage form rather than by relying on a single headline expiration date. Ingrezza has a layered estate, so the earliest expiring patent does not necessarily determine the first lawful generic launch date.

How strong was Neurocrine's patent estate?

Neurocrine's estate had meaningful structural strength because it was not limited to one patent category. A compound patent can provide broad protection, while formulation and method-of-use patents create additional litigation positions.

Compound protection

Compound claims are generally the most commercially valuable because they can cover the active pharmaceutical ingredient regardless of a generic manufacturer's excipient selection. If valid and enforceable, compound claims can block most conventional generic products until expiration.

Formulation protection

Formulation patents are narrower. Their strength depends on whether the generic product uses the claimed composition, concentration, capsule architecture, release profile, or manufacturing process. A generic applicant can sometimes design around these claims.

Method-of-use protection

Method-of-use patents can support a partial-label strategy. Under a section viii statement, a generic applicant may omit patented indications from its labeling while seeking approval for unpatented uses. The strategy is less effective when the patented indication is central to the commercial market or when the proposed label still encourages the patented use.

Manufacturing and process barriers

Manufacturing patents may add enforcement leverage, but they are harder to use against a generic before discovery establishes the actual production process. Process claims can be commercially important where the active ingredient has complex stereochemistry, purification requirements, or specialized intermediates.

Which FDA exclusivities affected generic valbenazine?

FDA regulatory exclusivity and patent protection are separate. FDA approved Ingrezza for tardive dyskinesia in 2017 and later approved the Huntington's disease chorea indication. Any applicable regulatory exclusivity periods did not replace the patent litigation but could affect the timing of final approval.

The key regulatory mechanisms were:

Regulatory mechanism	Relevance
New chemical entity exclusivity	Delays ANDA submission for the statutory period after approval
Three-year exclusivity	Can protect qualifying new clinical investigations and indication changes
30-month stay	Delays FDA approval after a timely patent suit
Paragraph IV first-filer exclusivity	May give the first qualifying ANDA challenger 180 days of generic exclusivity
Pediatric exclusivity	Can add six months to qualifying patents and exclusivities

For a commercial launch analysis, the later of the effective patent barrier and applicable FDA exclusivity is not always the correct measure. A patent may be invalidated, disclaimed, delisted, or found not infringed, while regulatory exclusivity may remain independently enforceable.

Did Zydus face generic launch risk before patent expiration?

Yes. Zydus' Paragraph IV filing created a potential early-entry pathway, but launch risk depended on the litigation outcome and any negotiated resolution.

The principal scenarios were:

Scenario	Result
Neurocrine wins on valid, infringed claims	Zydus remains blocked until the relevant patent barrier expires
Zydus wins on invalidity	FDA may approve the ANDA after removal of the regulatory stay
Zydus wins on noninfringement	The challenged patents do not block launch
Settlement	Entry date depends on the agreement and antitrust review
Partial victory	Zydus may launch with a modified formulation or skinny label
At-risk launch	Zydus launches before final resolution and assumes damages and injunction risk

An at-risk launch can expose the generic applicant to damages if the branded company later prevails. That risk is particularly material for a high-growth branded product with substantial prescription volume.

What litigation and settlement issues mattered?

The case presented the standard Hatch-Waxman issues:

• Whether the asserted patents were valid.
• Whether Zydus' ANDA product infringed the asserted claims.
• Whether the claims were enforceable.
• Whether the patents were properly listed in the Orange Book.
• Whether Zydus could avoid infringement through formulation or labeling changes.
• Whether the parties reached an entry-date settlement.

A settlement could establish a licensed launch date before full patent expiration. Such agreements often include a release, a license to the challenged patents, a no-launch provision before the agreed date, and provisions governing authorized generic competition. The economic value of the settlement depends on the launch date, product strength coverage, and whether Neurocrine retains the ability to launch or authorize another generic.

A docket dismissal alone does not disclose the commercial terms of a confidential settlement. The dismissal must be reviewed together with the court's order, any public settlement filing, and FDA approval history.

What is the current litigation status?

The case should be analyzed through the federal docket and FDA's ANDA records rather than through the filing date alone. The relevant status questions are whether:

1. The court entered a final judgment.
2. The action was dismissed pursuant to settlement.
3. The 30-month stay expired or was terminated.
4. Zydus received final FDA approval.
5. Zydus launched commercially.
6. Neurocrine listed additional patents after the original complaint.
7. Later patents generated separate litigation.

The civil action number identifies the original dispute, but later Ingrezza patent litigation may involve different patents, different dosage forms, or different generic applicants. A favorable resolution for Neurocrine in one action does not automatically block every later ANDA.

How does this case affect Neurocrine's revenue exposure?

Ingrezza is Neurocrine's principal commercial product and a major source of company revenue. Generic entry could affect revenue through:

• Immediate price erosion.
• Pharmacy substitution.
• Reduced net sales and gross margin.
• Lower treatment persistence.
• Payer pressure before actual generic launch.
• Loss of market exclusivity for one or more indications.
• Increased discounting and contracting costs.

The financial effect depends on the number of generic entrants. A single authorized or first-filer generic may produce a different erosion curve from several independent ANDA approvals. Product strength, payer coverage, indication mix, and the availability of a skinny-label product also matter.

How does Ingrezza compare with competing VMAT2 drugs?

Ingrezza competes principally with deutetrabenazine, marketed as Austedo by Teva Pharmaceuticals, and tetrabenazine, marketed as Xenazine and available in generic form.

Product	Active ingredient	Manufacturer	Primary movement-disorder markets	Competitive patent issue
Ingrezza	Valbenazine	Neurocrine	Tardive dyskinesia; Huntington's disease chorea	Layered compound, formulation, and method-of-use estate
Austedo	Deutetrabenazine	Teva	Tardive dyskinesia; Huntington's disease chorea	Separate Teva patent estate and generic challenges
Xenazine/generic tetrabenazine	Tetrabenazine	Lundbeck and generic manufacturers	Chorea and related disorders	Older molecule with greater generic exposure

Ingrezza's commercial differentiation includes once-daily dosing and strong positioning in tardive dyskinesia. Generic entry would increase pricing pressure in the VMAT2 category and could shift payer preferences toward valbenazine or competing products depending on formulary terms.

Key Takeaways

• The case is a Hatch-Waxman dispute over generic valbenazine and Neurocrine's Ingrezza product.
• Zydus' Paragraph IV certification triggered the patent litigation and the statutory FDA approval stay.
• Neurocrine's protection depends on a layered estate covering the molecule, formulations, and therapeutic uses.
• Compound claims present the broadest barrier; formulation and method-of-use claims are more vulnerable to design-around and skinny-label strategies.
• The civil action's final commercial effect depends on the judgment, dismissal terms, FDA approval status, and any subsequent Ingrezza patent litigation.
• Generic entry could materially affect Neurocrine because Ingrezza is a core revenue product.
• The case does not, by itself, establish a universal launch date for all generic valbenazine products.

FAQs About the Neurocrine-Zydus Ingrezza Litigation

What ANDA did Zydus file for Ingrezza?

Zydus filed an ANDA seeking approval for generic valbenazine capsules corresponding to Neurocrine's Ingrezza product. The precise ANDA number and approved strengths should be confirmed against FDA records and the litigation pleadings.

Did Zydus receive 180-day generic exclusivity?

A Paragraph IV certification does not, by itself, establish eligibility for 180-day exclusivity. Eligibility depends on first-filer status, forfeiture rules, and FDA's treatment of the ANDA under the applicable statutory provisions.

Can Zydus launch only a non-infringing indication?

Potentially. A section viii or skinny-label approach can omit patented indications, but it does not protect conduct that induces infringement or a product whose remaining labeling supports the patented use.

Are Ingrezza patents enforceable outside the United States?

U.S. patents apply only in the United States. Neurocrine must enforce corresponding national patent rights separately in other jurisdictions, subject to local patent, regulatory, and litigation rules.

Does dismissal of the Delaware case mean generic Ingrezza can launch immediately?

No. Dismissal may reflect a settlement, consent judgment, procedural resolution, or another disposition. FDA approval, patent status, settlement restrictions, and additional listed patents must be evaluated before determining launch rights.

References

1. U.S. District Court for the District of Delaware. (2022). Neurocrine Biosciences, Inc. v. Zydus Pharmaceuticals (USA) Inc., No. 1:22-cv-00439-RGA. PACER docket.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Orange Book.

3. U.S. Food and Drug Administration. (2017). FDA approves Ingrezza capsules for tardive dyskinesia. FDA.

4. U.S. Code. (2023). 21 U.S.C. § 355, abbreviated applications and patent certifications.

5. U.S. Code. (2023). 35 U.S.C. § 271(e)(2), infringement based on submission of an abbreviated new drug application.